Lae002int2001- An Open-Label Randomized Active-Controlled Phase II Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer
Posted Date: Nov 24, 2020
- Investigator: Thomas Herzog
- Specialties: Cancer, Gynecologic Oncology, Oncology, Ovarian Cancer
- Type of Study: Drug
This is an Open Label Randomized Active Controlled Phase II Clinical Study assessing the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients With platinum-resistant ovarian cancer. Efficacy will be measured by determining the rate of progression free survival.
Criteria:
To Be Eligible: Confirmed High Grade Serous Oc, Endometroid Oc, Or Ovarian Clear Cell Carcinoma, Received Prior Treatments With Bevacizumab Followed By Disease Progression, Or Contraindiction To Bevacizumab, Ecog 0-1, Life Expectancy >6 Months, No Other Active Cancer Within 3 Years, No Hypersensitivity To Study Drugs Or Excipients, No Co-Morbidity Deemed Severe By The Pi
Keywords:
Ovarian Cancer
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com